Treatment Outcomes for Opiate Addicted Pregnant Women by Roth Parr, Jennifer L
University of Kentucky 
UKnowledge 
DNP Projects College of Nursing 
2015 
Treatment Outcomes for Opiate Addicted Pregnant Women 
Jennifer L. Roth Parr 
University of Kentucky, jennifer.parr@esh.ukhc.org 
Follow this and additional works at: https://uknowledge.uky.edu/dnp_etds 
 Part of the Psychiatric and Mental Health Nursing Commons 
Right click to open a feedback form in a new tab to let us know how this document benefits you. 
Recommended Citation 
Roth Parr, Jennifer L., "Treatment Outcomes for Opiate Addicted Pregnant Women" (2015). DNP Projects. 
34. 
https://uknowledge.uky.edu/dnp_etds/34 
This Practice Inquiry Project is brought to you for free and open access by the College of Nursing at UKnowledge. It 
has been accepted for inclusion in DNP Projects by an authorized administrator of UKnowledge. For more 
information, please contact UKnowledge@lsv.uky.edu. 
STUDENT AGREEMENT: 
I represent that my DNP Project is my original work. Proper attribution has been given to all 
outside sources. I understand that I am solely responsible for obtaining any needed copyright 
permissions. I have obtained and attached hereto needed written permission statements(s) 
from the owner(s) of each third‐party copyrighted matter to be included in my work, allowing 
electronic distribution (if such use is not permitted by the fair use doctrine). 
I hereby grant to The University of Kentucky and its agents a royalty-free, non-exclusive and 
irrevocable license to archive and make accessible my work in whole or in part in all forms of 
media, now or hereafter known. I agree that the document mentioned above may be made 
available immediately for worldwide access unless a preapproved embargo applies. I also 
authorize that the bibliographic information of the document be accessible for harvesting and 
reuse by third-party discovery tools such as search engines and indexing services in order to 
maximize the online discoverability of the document. I retain all other ownership rights to the 
copyright of my work. I also retain the right to use in future works (such as articles or books) all 
or part of my work. I understand that I am free to register the copyright to my work. 
REVIEW, APPROVAL AND ACCEPTANCE 
The document mentioned above has been reviewed and accepted by the student’s advisor, on 
behalf of the advisory committee, and by the Assistant Dean for MSN and DNP Studies, on 
behalf of the program; we verify that this is the final, approved version of the student's DNP 
Project including all changes required by the advisory committee. The undersigned agree to 
abide by the statements above. 
Jennifer L. Roth Parr, Student 
Dr. Patricia Howard, Advisor 
  
Final DNP Practice Inquiry Project Report 
Treatment Outcomes for Opiate Addicted Pregnant Women 
 
Jennifer Roth Parr, RN, APRN 
 
 
University of Kentucky 
College of Nursing 
Spring 2015 
 
 
 
 
 
 
 
 
 
Patricia Howard, PhD, RN – Committee Chair 
Peggy El-Mallakh, PhD, APRN 
Chizimuzo Okoli, PhD, RN 
 
iii 
 
 
Acknowledgments 
I would like to thank Dr. Patricia Howard for encouraging me since 1993 by 
mentoring me throughout the Master’s program, being constantly supportive, allowing 
me to be her first research assistant, and then finally lending her expertise as I finish my 
DNP.  She is a true gem.  I would not have finished the Master’s program without her 
encouragement and never have gotten to this place.   I would also like to thank Dr. Zim as 
we like to call him or Dr. Okoli for his patience and invaluable help with steering me in 
the direction on a final practice inquiry project and then lending his expertise with 
statistical methods.  A hearty thank you to Dr. El-Mallakh for meeting with me and 
helping me to fine tune my academic writing and sharing her wisdom and 
encouragement.  I would also like to mention Whitney Kurtz-Ogilvie for her instrumental 
help in making me a better writer.   Finally I would like to thank my family for bearing 
with me throughout this process.   
 
 
 
 
 
 
 
 
 
iv 
 
 
 
 
TABLE OF CONTENTS 
Acknowledgements ..................................................................................................... iii 
Table of Contents ........................................................................................................ iv 
List of Tables and Figures ............................................................................................. v 
Introduction .............................................................................................................................................. vi 
Manuscript 1:  Pregnancy and Opiate Addiction:  A Review of the Literature……. 1 
Manuscript 2: The Role of the Advanced Practice Nurse in the Treatment of 
Addiction Disorders:  Advocacy, Leadership, and Lobbying to Influence Public    
Policy .......................................................................................................................... 26 
Manuscript 3:  Effective Inpatient Treatment Methods for Opiate Addicted Pregnant                
Women:  A Retrospective Chart Study ...................................................................... 46 
Practice Inquiry Project Conclusion .............................................................................. 62 
References .................................................................................................................. 64 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
v 
 
 
 
 
 
List of Tables and Figures 
 
 
Figure 1 ...................................................................................................................... 34 
Table 1 ........................................................................................................................ 58 
Table 2 ........................................................................................................................ 59 
Figure 2 ...................................................................................................................... 60 
Table 3 ........................................................................................................................ 61 
  
vi 
 
 
Introduction 
 
The problem of opiate addiction is complex enough but compounded when the 
patient is pregnant.  Substance use during pregnancy produces harmful and costly effects 
to both the mother and the fetus (Veilleux, Colvin, Anderson, York & Hines, 2010).    
The rate of opiate addiction among pregnant women in the U.S. has been increasing in 
epidemic numbers since the beginning of the 21st century.  This paper looks at research 
on the origin of the problem, the demographics of the average pregnant opiate addicted 
patient, the effects on the woman and her unborn child, and available treatment options.     
Preparation at the practice doctorate level includes advanced education to help 
become a change agent for populations in need, such as pregnant opiate addicted women 
and their unborn children.  The DNP prepared nurse is well positioned to assist this 
vulnerable population by using expert knowledge to influence health care outcomes for 
the pregnant opiate addicted patients.  This specific population is often ostracized and 
stigmatized which can deter their seeking available treatment.  As an example, in 2014, a 
law was passed in Tennessee that allows women to be criminally charged with an 
assaultive offense for the illegal use of a narcotic drug while pregnant or if her child is 
born addicted to or harmed by the narcotic drug; and for criminal homicide if her child 
dies as a result of her illegal use of a narcotic drug taken while pregnant.  A felony 
assault charge can subject such woman up to 15 years in prison in Tennessee.  
Further, pregnant opiate addicted women face stigma from healthcare 
professionals. As an example, a systematic review of 28 studies examining stigma by 
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healthcare professionals toward patients with substance use disorders concluded that 
negative attitudes of healthcare professionals toward patients with substance use 
disorders are common and contribute toward suboptimal outcomes (Van Boekel, 
Brouwers, Van Weeghel, and Garretson, 2013).  The DNP prepared nurse has a unique 
opportunity to contribute to positive treatment outcomes by providing direct care and 
assist with the management of care for these individuals.   In addition, the DNP prepared 
nurse can develop and implement healthcare policies to enhance access to often sparsely 
available and expensive care.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
Application of the DNP Essentials led to the development of this project.  In 
examining DNP Essential Number V, Health Care Policy for Advocacy in Health Care, it 
became apparent that this Essential would be instrumental in making effective changes 
for the population at hand.  Therefore a thorough investigation of the policy underlying 
drug addiction treatment methods and availability was conducted.    
DNP Essential III, Clinical Scholarship and Analytical Methods for Evidence-
Based Practice was also used to develop this project and find solutions for the treatment 
needs of the population.  The population of pregnant opiate addicted women is an area 
where a gap in literature exists, in terms of their experience and their needs for treatment.  
Information on the effects of the use of drugs on the fetus is readily available but not on 
preferred treatment methods and treatments that actually work for this group of women.   
This practice inquiry project will further present three manuscripts that explore 
the issue of opiate drug addiction.  The first manuscript is an integrative review of the 
literature regarding pregnancy and opiate addiction. It examines research that focuses on 
the issues faced by pregnant women who use and abuse opiates, such as access to care, 
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drug replacement therapy, and neonatal abstinence syndrome.  
  The second manuscript analyzes the role of the advanced practice nurse in the 
treatment of addiction disorders and how these nurses are uniquely suited to advocate and 
be leaders and lobbyists to influence public policy for this population.  The third 
manuscript is based on a retrospective chart review of data from 161 pregnant women 
with opiate addiction admitted to an inpatient psychiatric facility over a one year period 
and describes their treatment needs and prn usage in relation to their disposition at 
discharge.  The combined information from these three manuscripts will be used as a 
blueprint to offer evidence-based practice recommendations for primary care and 
psychiatric care providers to enhance their practices with this population.   
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Manuscript #1 
Pregnancy and Opiate Addiction:  A Review of the Literature 
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Abstract 
 
 
This paper is a review of 12 research articles, published between 1997 and 2014, 
which investigate the treatment of pregnant women with opiate addiction. The 
significance of the problem of opiate addiction and pregnancy and the resulting neonatal 
abstinence syndrome cannot be overestimated.   By identifying effective treatment 
strategies for this population to treat opiate withdrawal symptoms management and 
addiction treatment options, the quality of life for these women and unborn children can 
be enhanced.   
 
 Keywords:  opiates, pregnancy, addiction 
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Opiate Addiction, Pregnancy and Treatment Modalities:  A Review of the 
Literature 
The use and misuse of both prescription and illegally obtained opiates has become 
an epidemic and costly public health problem among pregnant women in the United 
States.  Martin, Longinaker, and Terplan, (2014) reported that during the period from 
1992-2012, 2% to 28% of pregnant women in the United States sought treatment for 
abuse of prescription opioids and that 1% to 19% were admitted for treatment of 
prescription opioids.  According to the Substance Abuse and Mental Health Services 
Administration (SAMHSA) combined data for 2007 and 2008, 5.1% of pregnant women 
ages 15–44 reported past month use of illegal drug use which could include abuse of 
prescription medications obtained “on the street” (SAMHSA, 2009).  The rate of current 
illicit drug use of all types in combined data from SAMHSA (2013) was 14.6 percent 
among pregnant women aged 15 to 17, 8.6 percent among women aged 18 to 25, and 3.2 
percent among women aged 26 to 44. 
Treatment options for pregnant women with opiate addictions include 
detoxification or drug replacement therapy with methadone or buprenorphine. Regardless 
of the treatment approach, withdrawal from opiates is difficult for pregnant women.  An 
important research question is: Which treatments are available to hospitalized pregnant 
women with opiate addiction and what are their options for treatment when discharged 
from the hospital setting?  Nursing care can be improved and tailored to fit the needs of 
the patient population when the effectiveness of current treatment methods are researched 
and examined.   
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 Substance use during pregnancy is associated with harmful effects to both the 
mother and fetus.  According to Patrick (2012), from 2000 to 2009 the number of 
newborns with neonatal abstinence syndrome resulting from the mother’s use of drugs 
during pregnancy tripled and the number of mothers using opiates at delivery increased 
five-fold from 1.10 to 5.63 per 1,000 births.  Jackson and Shannon (2012) report that one 
of the most devastating prenatal effects of using opiates is the repeated periods of 
intoxication and withdrawal which can result in life threatening complications for the 
fetus as well as postnatal complications of neonatal abstinence syndrome. 
Opiate addicted pregnant women are a very specific population with specific 
needs.  Standard of care would necessitate a universal substance use screening during 
pregnancy and referral to treatment such as maintenance therapy if warranted.  When a 
woman is identified as pregnant and opiate addicted, evidence-based practice guidelines 
and research recommend referral for short term hospitalization for opiate detoxification, 
followed by then treated with methadone or buprenorphine as a safer substitute on a 
maintenance basis.  However, according to Martin et al. (2014), only about a third of the 
women hospitalized when pregnant for opiate addiction are placed on medication assisted 
therapy despite the standard of care for opioid abuse in pregnancy.  A comprehensive, 
standard of care program regimen improves maternal and neonatal outcomes as well as 
reduces associated adverse health consequences (Jones, O’Brady, Malfi, & Tuten, 2008; 
Kaltenbach & Finnegan, 1998). 
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Significance/Morbidity/Mortality 
The significance of the problem of opiate addiction and pregnancy and the 
resulting neonatal abstinence syndrome cannot be overestimated.  The recent trends in 
opioid use with women are alarming.  The overall rate of heroin initiation increased for 
women from 0.06% in 2002-2004 to 0.10% in 2009-2011 (SAMHSA, 2013).  There has 
been a 50% increase in persons 12 and older who are dependent on heroin from 180,000 
in 2007 to 360,000 in 2011 (SAMHSA, 2013).  There has been greater than a 500% 
increase among women in opioid pain reliever overdose deaths since 1999 with opioid 
overdoses surpassing motor vehicle accidents as a leading cause of death (CDC, 2014).  
In addition, in the U.S., 25% or more of all pregnant women admitted for treatment report 
prescription opioid use (CDC, 2014).  
Neonatal Abstinence Syndrome (NAS), which is observed in infants of a mother 
who has been using opiates, occurs in 55-94% of exposed infants with medication 
required in approximately 50% of the cases (Kahila, Saisto, Kivitie-Kallio, Haukamaa, & 
Halmesmaki, 2007).   The mean length of stay for infants with NAS is 16.4 days at an 
average cost of $53,000.00 per infant (Martin, Longinaker, & Terplan, 2014).  
Complications from NAS include dysfunction in feeding, gastrointestinal dysfunction, 
autonomic dysfunction, failure to thrive, seizures, low birth weight for gestational age, 
and respiratory problems (Martin, et al., 2014).  The abuse of heroin or other opiates 
during pregnancy is associated with a 600% increase in prenatal obstetric complications 
(SAMSHA, 2013). Babies who are born to opiate-abusing mothers have lower birth 
weights, and these infants are at greater risk of sudden infant death syndrome (SIDS).  
Opiate-abusing mothers tend to have decreased health and poor nutrition, are less likely 
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to get adequate prenatal care, and are more likely to abuse other dangerous substances 
(SAMSHA, 2013).   
The purpose of this paper is to summarize findings from a literature review that focused 
on treatment preferences and needs of opiate addicted pregnant women and research on 
current treatment.  In addition, this paper will examine the gaps in research, and make 
recommendations for evidenced based practice to improve the quality of life for this 
unique population of women and children. 
Review of the Literature 
Search Methodology 
  An integrative review of literature relating to treatment needs of pregnant opiate 
addicts was conducted.  The online databases used for the search included the Cumulative 
Index to Nursing and Allied Health Literature (CINAHL), PsycINFO Psychology 
Information, MEDLINE, the Cochrane Database of Systemic Reviews, Article First and 
Elsevier.  Key words used in the search were pregnant, opiate addicts, users, dependence 
and women.  In additions, retrieved studies were graded on the strength of evidence based 
on the Strength of Recommendation Taxonomy (SORT) criteria (see Annotated 
Bibliography). 
Inclusion and Exclusion Criteria 
       Initial inclusion criteria comprised any study that contained information 
regarding both opiate addiction in general and pregnant women with opiate addiction and 
treatments for this population that met quality and evidence grading standards published 
in the 5-year period prior to 2012.  The literature was screened to make sure that it 
represented the population of opiate addicted pregnant women whenever possible. 
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Following this initial review of articles obtained in the search, exceptions were made 
because two studies older than the 5-year mark had a strong evidence rating.  In addition, 
some articles were not excluded even though they addressed opiate addiction as a whole 
because they were landmark studies of high quality involving opioid addiction.   
Exclusion criteria encompassed studies focused on addiction in general (not specific to 
opioids) or the physiological effects on the newborns of addicted women.   
Findings 
Twelve studies focused on the criteria mentioned above and were included in this 
evidence review.  The twelve studies can be categorized into studies which focused solely 
on opiate addiction and pregnancy from a drug replacement therapy perspective, and 
those that investigated both pharmacologic treatment and other factors determined to be 
equally important to treatment success.  
Treatment Modalities 
Drug Replacement Therapy 
 A significant amount of research has examined the effects of opiate addiction on 
the developing fetus and on the infant after birth.  In addition a large amount of research 
has been completed which favors drug replacement therapy in lieu of detoxification for 
the pregnant opiate addicted woman.   
 The studies focusing on drug replacement therapy for the opiate addicted pregnant 
woman recommend either methadone or buprenorphine as the drug of choice to prevent 
opiate abuse in women during pregnancy.  Some researchers conclude that methadone is 
superior while others claim buprenorphine is, yet some state either will be equally 
efficacious.   
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 In an example of a study that recommends methadone as the drug of choice, 
Burns, Mattick, Lim, and Wallace (2007) reported on a systematic review of descriptive 
studies using record linkage in the U.S. There were 2993 births to women on methadone 
at delivery; these increased from 62 in 1992 to 459 in 2002.  The authors concluded that 
continuous methadone treatment during pregnancy was associated with earlier antenatal 
care and improved neonatal outcomes.  Early engagement in methadone treatment by 
pregnant women with opiate addiction was identified as essential. Study limitations 
include the fact that due to the cross sectional nature of the reviewed studies cause and 
effect could not be determined.  The study controlled only for confounding variables on 
main neonatal outcomes and future work would need to examine relationships between 
variables in more detail.  Another limitation is that the study did not have information on 
methadone dosage or treatment policies, critical knowledge affecting retention and 
outcomes.   
 Another study, which supported methadone maintenance, was a Cochrane 
systematic review of multiple randomized clinical trials among opiate addicted 
individuals in different countries by Mattick, Breen, Kimber, and Davoli (2009).  This 
study, although not specific to pregnant women was included because of its significance 
and the large number of subjects (n=1969).  The authors found that methadone 
maintenance treatment had superior treatment effectiveness as compared to treatments 
that did not involve opioid replacement therapy such as detoxification, drug rehabilitation 
or placebo medications.  In this study, methadone maintenance treatment was shown to 
retain patients in treatment, which is considered paramount to treatment effectiveness.  
The theme of treatment retention was prevailing in the studies for success of treatment. 
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 However, a retrospective case series study of 23 infants born to 22 pregnant 
women in the U.S. by O’Conner, Alto, Musgrave, Gibbons, Llatno, and Karnes (2011) 
found that buprenorphine was the best available practice for opioid dependent pregnant 
women and the early identification and treatment of this at risk population is essential to 
reduce complications and decrease withdrawal for the neonate.  In agreement with the 
O’Conner et al.’s (2011) study, Kahila, Saisto, Kivitie-Kallio, Haukamaa, and 
Halmesmaki (2007) conducted a case-control study among 66 pregnant women in 
Finland and buprenorphine was again found as the preferred treatment option for opioid 
addicted pregnant women.  This study mentioned that drug replacement therapy such as 
the use of buprenorphine prevents relapses, raises social status of the women and helps 
avoid infectious disease transmission, overdose death and criminality associated with 
street drugs.  Their findings also state that it improves overall maternal health and life 
circumstances and thus decreases the risk to the fetus.   
An earlier high quality RCT performed by Mattick et al. (2002) with a sample of 
405 opioid dependent subjects in the U.S., found that both methadone and buprenorphine 
were effective in treating opioid dependence by producing significant reductions in drug 
use.  Changes in well-being and social functioning were also noted as significant.    
Drug Replacement and a Holistic Approach  
Studies involving treatment interventions reiterated the importance of drug 
replacement therapy but suggested that something else was needed for treatment success.  
In a review of opiod dependence among pregnant women in different countries, Unger, 
Metz, and Fischer (2012) found that using opioid agonist maintenance treatment was the 
best option for the majority of women, noting that few opioid addicted women could 
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handle abstinence from opioids.  They mention that treatment, however, should involve 
more than just replacement therapy and should be an interdisciplinary team approach that 
includes social workers, nurses, psychologists, psychiatrists, gynecologists, 
anesthesiologists and pediatricians.  They also recommend the treatment of comorbid 
psychiatric conditions and addressing the financial, legal and housing aspects as well as 
offering psychosocial support.  A review of the literature by Veilleux, Covlin, Anderson, 
York, and Heinz, (2010) reiterated the need for psychosocial interventions and 
specifically mentioned outreach counseling and brief outpatient therapy to decrease 
relapse and retain the individuals in treatment.  In a case series study in the U.S. by Jones, 
Martin, Heil, Kaltenback, Selby, Coyle, Stein, Arria, and Fischer (2008), the study 
authors stated that the optimal treatment approaches for opioid dependent pregnant 
women should be tailored to the needs of each patient and such tailored treatment needs 
to be further investigated.  Jones et al. (2008) also noted that opioid dependent pregnant 
women face huge stigma from family and society and that health care providers can 
mitigate this source of stress by directly addressing the patient’s fears, guilt and treatment 
resistance.   
Lack of Treatment Accessibility 
In a case review study of 420,665 cases in the U.S., Martin et al. (2014) looked at 
recent trends in treatment admissions for prescription opioid abuse during pregnancy. A 
significant finding in this study was that only a small proportion of the women with 
opioid addiction were receiving medication-assisted therapy.  The researchers note that 
mediation-assisted therapy is the standard of care for opioid dependent pregnant women, 
indicating that it leads to improved maternal medical status, decreased fetal morbidity 
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and increased utilization of prenatal care.  The authors attribute the lack of access to the 
medication-assisted therapy, stating that only 9% of substance abuse treatment facilities 
in the US offer medication-assisted therapy (Martin et. al, 2014).  
 
Gaps in literature 
There is a plethora of research supporting the use of drug replacement therapy in 
opiate addicted individuals (Mattick et al., 2006; O’Conner et al., 2011; Kahila et al., 
2007; Mattick et al., 2009; and Veilleux et al., 2010).  These same studies give scientific 
support for the use of opioid replacement therapy in opiate addicted pregnant women.  
The gaps in the literature involve the following questions:  
1)  What is the preferred method of treatment for opiate addicted pregnant women when 
identified as pregnant, detoxification from opiates or drug replacement therapy?  Do they 
prefer buprenorphine or methadone if they prefer drug replacement therapy?   
2)  Why are women not being offered drug replacement therapy when pregnant and 
opiate addicted if it is known to be the standard?  
3)  What type, if any, of comprehensive approaches to treatment have shown to achieve 
long-term effects with this vulnerable population?   
Implications for Future Research 
      The research included in this review suggests that drug replacement therapy is the 
standard in treatment for opioid addicted pregnant women.  Some research further 
suggests that giving methadone or buprenorphine alone is inadequate.  Rather, many of 
the researchers point out that there is a need for a multidisciplinary approach beyond drug 
replacement therapy to create lasting change and make a difference in the lives of the 
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women and newborn children.  Perhaps longitudinal studies of these women and their 
children would provide a blueprint and help guide clinicians further in other areas that 
could promote increased quality of life for the women and children.   
Nursing Practice Change Recommendations 
  According to Young, Borden and Shea (2014) in their webinar presentation on 
treatment needs for opiate addicted mothers in the U.S., barriers to best practice for this 
unique population include:  1) the variation in the child welfare response, 2) the lack of 
medication availability, 3) the lack of collaboration between social services, healthcare 
professionals, state, local agencies and law enforcement, 4) the lack of sufficient 
comprehensive, long term treatment for women and their children and5) the knowledge 
and practice gaps in best practices in screening and assessment of addiction in pregnancy, 
post pregnancy, and neonatal abstinence syndrome.   
Advanced practice nurses are in a unique position to assist in the development and 
implementation of this type of collaborative approach, in which a team would develop a 
plan to identify women with opioid use during pregnancy and engage them in prenatal 
care, medical care, substance use treatment and other needed services, (AACN DNP 
Essentials, 2006).  This approach is believed to reduce the number of crises at birth for 
women, babies and the system (Young et al, 2014).     
Conclusion 
There are immediate benefits of opioid replacement therapy for pregnant women 
addicted to opiates. Through treatment with either methadone or buprenorphine, the 
woman is able to remain off unsafe street drugs and health risks to the unborn child are 
reduced, although neonatal abstinence syndrome is still likely. The risk to the fetus and 
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mother is reduced as indicated by several groups of researchers who have explored the 
topic (Mattick et al. 2009; Kahila et al. 2007; Martin et al. 2014). Further research is 
needed to help determine what would enable pregnant women addicted to opiates to 
remain off of street drugs and enhance her ability to remain drug free.  Further studies on 
what constitutes effective lasting treatment and that would have long-term positive 
impact on the lives of the women and their children would be optimal. 
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Annotated Bibliography 
Author/Year/Journal/Title 
Reference Information 
 
Burns, L, Mattick, R.P., Lim, K & Wallace, 
C./2007/Addiction 102:  264-270/Methadone in pregnancy:  
treatment retention and neonatal outcomes 
Type of Literature/Design 
 
Cross Sectional; SR of Descriptive Studies using Record 
Linkage 
 
 
Sample 2993 births in 10 year period from 1992 – 2002. 
 
Purpose of Article Examine the association between retention in methadone 
treatment during pregnancy and key neonatal outcomes. 
Findings Continuous methadone treatment during pregnancy is 
associated with earlier antenatal care and improved neonatal 
outcomes. 
Implications Innovative techniques for early engagement in methadone 
treatment by pregnant opioid women or those planning to 
become pregnant should be identified and implemented. 
Evidence Level 2 
Grade Strength A 
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Author/Year/Journal/Title 
Reference Information 
 
O’Connor, A., Alto, W., Musgrave, K, Gibbons, D., Llatno, 
L., Holden, S., & Karnes, J./2011/J Am Board Fam Med 24:  
104-201/Observational study of buprenorphine treatment of 
opioid-dependent pregnant women in a family residency:  
reports on maternal and infant outcomes 
Type of Literature/Design 
 
Observational study; Retrospective case studies 
Sample 23 infants born to 22 women 
Purpose of Article To investigate the outcomes of infants who were exposed to 
a range of doses of buprenorphine in utero and to determine 
how closely observed maternal/fetal outcomes match those 
previously reported in the literature 
Findings The findings were consistent with earlier studies in that 
early identification and treatment of opioid dependent 
pregnant women is essential because it reduces potential 
complications from recurrent intoxication and withdrawal 
from opioids for both fetus and mother. 
Implications Buprenorphine, a replacement for opioids, is the best 
available practice for opioid dependent pregnant women. 
 
Evidence Level 3 
Grade Strength C 
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Author/Year/Journal/Title 
Reference Information 
 
Unger, A., Jung, E., Winklbaur, B. & Fischer, 
G./2010/Journal of Addictive Diseases 29, 217-230/Gender 
issues in the pharmacotherapy of opioid-addicted women:  
buprenorphine 
Type of Literature/Design 
 
Case Series 
Sample NA 
Purpose of Article Purpose is to increase awareness for the need to take gender 
into consideration when making treatment decisions in an 
effort to optimize services and enhance the quality of life of 
women suffering from substance abuse. 
Findings There are significant gender-related differences in the 
epidemiology of opioid dependence and maintenance 
treatment.  Evidence has suggested that neonatal abstinence 
following intrauterine exposure to buprenorphine may be 
less severe than associated with methadone.  Buprenorphine 
is gaining recognition as an effective treatment for opioid 
dependence.  Significant psychiatric co-morbidity such as 
mood disorders, PTSD and eating disorders add to challenge 
of attaining treatment success in women with substance 
abuse problems. 
Implications Data governing the use of buprenorphine is limited thus 
significant gender-related difference in the epidemiology of 
opioid dependence and maintenance treatment require more 
investigation. Optimizing treatment outcomes in terms of 
retention and completion requires consideration of barriers 
to treatment access and entry that are specific to women 
such as lack of services for pregnant women, fear of losing 
custody when the baby is born and fear of prosecution.  
Public funded studies and pharmaceutical support drug trials 
are needed to provide a better understanding of gender-
related differences in response to meds.  
. 
Evidence Level Level 3 
 
Grade Grade B 
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Author/Year/Journal/Title 
Reference Information 
 
Kahila, H., Saisto, T., Kivitie-Kallio, S., Haukamaa, M., 
Halmesmaki, E./2007/Acta Obstetricia et Gynecologica 86:  
185-190.  A prospective study on buprenorphine use during 
pregnancy:  effects on maternal and neonatal outcomes 
Type of Literature/Design 
 
Case control study, subjects followed prospectively in 
outpatient multidisciplinary antenatal setting 
Sample 67 pregnancies of 66 buprenorphine users from 2002 to 
2005 
Purpose of Article To determine via case-study the effects of buprenorphine 
use during pregnancy on maternal and neonatal outcome 
Findings Buprenorphine is more suitable for opioid maintenance 
therapy and toxicologically is safer than methadone.  It has 
no adverse effect on pregnancy and labor or immediately 
neonatal well-being.  The main problem with buprenorphine 
use is NAS.  The pregnancies and deliveries of 
buprenorphine-using women were uneventful but severe 
NAS and need for morphine replacement therapy was seen 
in 57% of buprenorphine exposed newborns. 
Implications  Replacement therapy with buprenorphine for opioid 
dependence during pregnancy is recommended in light of 
the fact that it prevents relapses, raises social status of the 
women and helps avoid infectious disease transmission, 
overdose death, and criminality associated with street drugs.  
It also improves maternal health and life circumstances and 
probably decreases risks to fetus. 
Evidence Level Level 2 Case Control 
Grade Strength A 
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Reference Information 
 
Mattick, R.P., Breen, C. Kimber, J. & Davoli, 
M./2009/Cochrane Collaboration Issue 3/Methadone 
maintenance therapy versus no opioid replacement therapy 
for opioid dependence (review) 
Type of Literature/Design 
 
SR of Multiple RCTs 
Sample 1969 participants 
Purpose of Article Purpose – To evaluate the effects of methadone maintenance 
treatment compared with treatments that did not involve 
opioid replacement therapy (detoxification, offer of drug 
free rehabilitation, placebo medication, wait list controls) for 
opioid dependence. 
Findings Methadone is an effective maintenance therapy intervention 
for the treatment of heroin dependence as it retains patients 
in treatment and decreases heroin use better than treatments 
that do not utilize opioid replacement therapy.  It did not 
show a statistically significant superior effect on criminal 
activity or mortality. 
Implications Methadone maintenance treatment can keep people who are 
dependent on heroin in treatment programs and reduce their 
use of heroin.  The review found that people withdraw from 
trials when they are assigned to a drug free program.   
Evidence Level Level 1 
Grade Strength A 
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Author/Year/Journal/Title 
Reference Information 
 
Mattick, R.P., Ali, R., White, J.M., O’Brien, S., Wolk, S. & 
Danz, C./2002/Addiction 98, 441-452/Buprenorphine versus 
methadone maintenance therapy:  a randomized double 
blind trial with 405 opioid-dependent patients 
Type of Literature/Design 
 
Randomized double-blind trial 
Sample 405 opioid-dependent patients seeking treatment 
Purpose of Article To assess the efficacy of buprenorphine compared with 
methadone maintenance therapy for opioid dependence in a 
large sample 
Findings Buprenorphine did not differ from methadone in its ability 
to deter heroin use but treatment retention was 10% less in 
the group receiving it.  The decreased percentage could be 
attributed to the method in which the medication was 
induced in treatment. 
Implications The results indicate that both methadone and buprenorphine 
are effective in treating opioid dependence by producing 
significant reductions in drug use.  Changes in addicts’ well-
being and social functioning were noted also.   
Evidence Level Level 1, high quality RCT 
Grade Grade A 
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Author/Year/Journal/Title 
Reference Information 
 
Unger, A., Metz, V. & Fischer, G./2012/Obstetrics and 
Gynecology International/Opioid dependent and pregnant:  
what are the best options for mothers and neonates 
Type of Literature/Design 
 
Review Article 
Sample NA 
Purpose of Article Update health professionals in the field of gynecology and 
obstetrics on the latest optimal treatment approaches for 
mothers suffering from opioid dependence and their 
neonates. 
Findings Women with opioid addiction are a highly vulnerable group 
and at risk of adverse pregnancy outcomes and perinatal 
complications.  Opioid agonist maintenance treatment is the 
best option for the majority of women.  Few opioid addicted 
women can handle abstinence from opioids and rapid 
detoxification is not recommended from a medical 
standpoint. 
Implications Early and closely monitored treatment in interdisciplinary 
team approach that includes social workers, nurses, 
psychologists, psychiatrists, gynecologists, anesthesiologists 
and pediatricians should be provided.  The treatment of co 
morbid psychiatric conditions and the resolution of 
financial, legal, housing issues and psychosocial support 
have significant effect on optimizing pregnancy outcom 
Evidence Level Level 3 
Grade Grade C 
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Author/Year/Journal/Title 
Reference Information 
 
Jones, H.E., Martin, P.R., Heil, S.H., Kaltenback, K., Selby, 
P., Coyle, M., Stine, S., O’Grady, K., Arria, A. & Fischer, 
G. /2008/Journal of Substance Abuse Treatment 35, 245-
259/Treatment of opioid dependent pregnant women:  
clinical and research issues 
Type of Literature/Design 
 
Case Series 
Sample NA 
Purpose of Article To address common question that clinicians face when 
treating pregnant women with opioid dependence. 
Findings Pregnant women often receive agonist maintenance 
treatment because the benefits supersede the risks.  The 
mother and child are now both considered equally important 
instead of making the mother “bad” and the baby the only 
reason for treatment.    
Implications Optimal treatment approaches that are tailored to the needs 
of each opioid dependent pregnant patient need to be 
investigated.  Opioid dependent pregnant women face huge 
stigma from family and society.  Health care providers can 
mitigate this source of stress by directly addressing the 
patient’s fears, guilt and treatment resistance.   
Evidence Level Level 3 
Grade Grade C 
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Author/Year/Journal/Title 
Reference Information 
 
Veilleux, J., Colvin, P., Anderson, J., York, C. & Heinz, 
A./2010/Clinical Psychology Review 30, 155-166/A review 
of opioid dependence treatment:  pharmacological and 
psychosocial interventions to treat opioid addiction 
Type of Literature/Design 
 
Review of Literature with focus drawn by experts in the 
field 
 
Sample  
Purpose of Article Up to date review of the literature on opioid dependence 
treatment, with focus on conclusions drawn by experts in the 
field (Cochrane reviews meta-analyses and methodological 
rigorous studies such as randomized controlled trials. They 
describe the major classes of drug treatments available, in 
the context of detoxification and long term treatment 
options.  They reviewed the state of the literature regarding 
prevention of opioid overdose and discuss co morbidity 
among opioid dependent populations.   
Findings Treatment retention is extremely important in successful 
outcomes with opioid addiction.  Two psychosocial 
interventions, outreach counseling and brief outpatient 
therapy plus contingency management resulted in lower 
relapse rates and higher treatment retention at baseline.  
Further research on psychopharmacological medications is 
needed. 
Implications Many treatment options for opioid dependence are available 
and many work fairly well.  Opioid addiction, however, is 
found to be chronic and unrelenting and often people drop 
out of treatment which exposes them to an at- risk lifestyle 
and decreased quality of life.  Hopefully generalizing the 
outcome research to real patient outcomes will assist in 
combating this addiction.   
Evidence Level Level 3, Expert Consensus 
Grade Grade C 
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Author/Year/Journal/Title 
Reference Information 
 
Pritham, U., Paul, J. & Hayes, M./2012/Association of 
Women’s Health, Obstetric and Neonatal Nurses 41, 180-
190/Opioid dependency in pregnancy and length of stay for 
neonatal abstinence syndrome 
Type of Literature/Design 
 
Retrospective descriptive study 
Sample 152 opioid dependent pregnant women 
Purpose of Article To examine opioid replacement therapy in pregnancy and 
neonatal outcomes, length of stay for neonatal abstinence 
syndrome. 
Findings Replacement therapy with either methadone or 
buprenorphine maintenance therapy caused prolonged 
hospital stays for neonates.  Breastfed neonates had shorter 
length of stay.  Prenatal exposure to methadone caused 
longer length of stay for neonate than infants with prenatal 
exposure to buprenorphine. 
Implications Harm reduction strategies for opioid dependent pregnant 
women should include guidance on daily treatment doses 
and recommendations to avoid concomitant use of benzos in 
order to lessen neonatal abstinence syndrome.  
Breastfeeding should be recommended.  Understanding 
perinatal and neonatal outcomes of pregnant women on 
replacement therapy will help identify optimal treatment for 
opioid dependency with pregnancy.   
Evidence Level Level 2 
Grade Strength C 
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Author/Year/Journal/Title 
Reference Information 
 
Crome, I., Khaled, M.K.Ismail, Ghetau, E., McAuley, R., 
Bloor, R., Jones, P. & O’Brien, P.M.S./2005/Drugs:  
Education, Prevention and Policy 12 (6) 431-436/Opiate 
misuse in pregnancy; finding of a retrospective case note 
series 
Type of Literature/Design 
 
Retrospective Case Series 
Sample 50 pregnant opiate addicted women 
Purpose of Article To identify the obstetric and neonatal characteristics of high-
risk pregnancies of opiate addicts, the level of contact with 
the offered service and the relationship between level of 
attendance in the service and pregnancy outcome. 
Findings Birth weights of 27 of 39 babies in the study were < or = 
to10th percentile for gestational age.  Positive association 
between attending the treatment services offered at least 
70% and birth weight.  Retention in treatment is associated 
with improved outcomes in pregnant drug users.   
Implications Participation in treatment programs for opiate addiction may 
give the stability needed in the life of an opiate addict.  It 
gives them the opportunity for substitution medication and 
also helped to resolve housing, employment and other social 
issues.  A program of research should be developed to 
examine the impact of maternal drug use on the children at 
birth to adolescence and evaluate interventions aimed at 
improving their health and well-being both short and long 
term. 
Evidence Level Level 3 
Grade Grade C 
 
Problem with study is that it is difficult to draw conclusion 
based on retrospective analysis of relatively small sample 
size.   
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Author/Year/Journal/Title 
Reference Information 
 
Martin, C., Longinaker, N., Terplan, M. /2014/Journal of 
Substance Abuse Treatment/Article in Press retrieved from:  
http://dx.doi.org./10.1016/j.jsat.2014.07.007.  Recent trends 
in treatment admissions for prescription opioid use during 
pregnancy 
 
Type of Literature/Design 
 
Case Review via TEDS Admissions Data 
Sample 420,665 cases reviewed 
Purpose of Article Examine trends in opioid pregnant women treatment 
admissions 
Findings Overall there were 420,665 substance abuse treatment 
admissions from 1992 to 2012.  Among pregnant admissions 
the proportion reporting any abuse of opiates rose from 2% 
in 1992 to 28% in 2012.    
 
Implications The small amount of opioid admissions receiving 
medication-assisted therapy is alarming.  The demand for 
treatment of prescription opioids during pregnancy has 
increased in recent years parallel to the increase in abuse 
among the general population.  As opioid abuse increases 
there is a need for increase services with a multidimensional 
approach to preventing its impact 
Evidence Level Level 2 
Grade Strength B 
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Abstract 
 
     This paper explores the role of the Advanced Practice Nurse in the treatment of 
addiction at the policy making level.  By using the strengths inherent in the Advanced 
Practice Role such as advocacy, leadership and lobbying, the DNP graduate can shape 
policy to create change.  Policy change is explored through the Kingdon Conceptual 
Framework.  The problem of opiate addiction in Kentucky is examined and current 
attempts to change the State legislative policy for the treatment of opiate addiction is 
presented with emphasis on the difference the Advanced Practice Nurse can make in 
implementing change.  
 Keywords:  opiates, Naloxone, policy 
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The Role of the Advanced Practice Nurse in the Treatment of Addiction Disorders:  
Advocacy, Leadership, Lobbying to Influence Public Policy 
Epidemic increases in the use of opiates and heroin throughout Kentucky are 
consistent with opiate use trends in the United States as a whole (Substance Abuse and 
Mental Health Services Administration [SAMHSA], 2010).  In addition, increased use 
has contributed to increased deaths from heroin and opiate overdose in the past decade.  
This paper explores how advanced practice nurses can influence the treatment of 
addiction in the policy arena by taking on the roles of advocate, leader and lobbyist.  One 
such way would be to help facilitate policy that would mandate the availability of 
Medicaid funding for inpatient opiate addiction treatment and increase the availability of 
naloxone to address the problems of opiate addiction and heroin deaths.  In this paper, the 
policy perspective for opiate and heroin addiction problems will be analyzed using 
Kingdon’s multiple streams theory.  A case study involving the introduction of Senate 
Bill 5, which involved increasing the availability of naloxone to overdosed heroin 
substance abusers and increasing treatment options to this population, and was 
unsuccessfully presented before the Kentucky legislature in the spring of 2014, will be 
highlighted.   
 Background and Significance of Opiate Addiction Problem   
Opiate drug abuse costs lives, affects the health of newborn infants born to 
abusing mothers and has a negative impact on epidemic numbers of individuals in the 
United States (SAMHSA, 2010).  The Network for Public Health Law (2014) states that 
fatal drug overdoses haves increased six-fold over the past three decades with 15,000 of 
these deaths attributed to opiates alone.  In 2010, The Centers for Disease Control 
estimated that over 78% of drug overdoses were unintentional, and those that were opiate 
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induced could have been prevented by an opioid antagonist such as naloxone.   Opiate 
overdose can be easily and inexpensively reversed through the timely administration of 
naloxone and emergency care (Wermerling, 2010), yet access to naloxone is limited due 
to laws and regulations that predate the overdose epidemic era.  
The problem exists on a national scope as well as statewide.  According to 
Kerlikowske (2012), drug induced deaths are the leading cause of injury death in the 
United States.  A 2009 SAMHSA report on substance abuse suggests that 19% of women 
ages 15 to 44 are addicted to opiates.  These data are critical when viewed within the 
context of consequences for women of childbearing age.  According to Patrick (2012), 
from 2000 to 2009 the number of newborns with neonatal abstinence syndrome resulting 
from the mother’s use of drugs during pregnancy tripled and the number of mothers using 
opiates at delivery increased fivefold from 1.10 to 5.63 per 1,000 births. 
Opiates, including prescription drugs, are the most commonly used drugs among 
primary drug treatment admissions in the state of Kentucky (SAMHSA, 2012).  
According to the Office of National Drug Control Policy (2012), Kentucky was one of 
the top ten states for rates attributed to non-medical use of pain relievers among persons 
aged 12-17.  Reports for 2010-2011 indicated that approximately 161,000 Kentuckians 
ages 12 and older used pain relievers for non-medical reasons (SAMHSA, 2012).  
Overdose deaths attributed to the use of heroin accounted for nearly one-fifth, or 19.56%, 
of all Kentucky Medical Examiner drug overdose cases in 2012.  In 2011 the rate was 
3.22%.  Of the 1,004 overdose deaths in 2011, 888 were found to be unintentional (Office 
of Drug Control Policy, State of Kentucky, 2012).    
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      Addressing the Problem: Advanced Practice Nurse Responsibilities 
      “Health policy influences multiple care delivery issues, including health 
disparities, cultural sensitivity, ethics, the internationalization of health care concerns, 
access to care, quality of care, health care financing, and issues of equity and social 
justice in the delivery of health care” AACN  (2006, p. 13).  According to the Institute of 
Medicine’s hallmark 2001 report, DNP graduates are “prepared to design, influence, and 
implement health care policies that frame health care financing, practice regulation, 
access, safety, quality and efficacy” (AACN, 2006, p. 13). DNP graduates are especially 
capable, according to the AACN (2006), of addressing issues of social justice and equity 
in health care due to their powerful practice experience, which can translate into strong 
influence on policy formation.  Thus DNP-prepared nurses are able to integrate their 
experience into effective action in the policy arena and help their patients receive access 
to care and equity in care. According to Goudreau and Smolenski (2013), advanced 
practice nurses “are already taking action to create better practice environments and 
conditions, investigating how they can work to define positive change for their patients/ 
clients, and how they can have an impact on the health of communities and the nation 
through the health policy process” (p. 305). 
The Advocate Role of the APN in Opiate Addiction Treatment 
Nursing as a discipline tends to resist political involvement; many nurses prefer to 
focus on helping patients directly. Lobbying in particular has developed a bad 
connotation and nurses historically avoid it.   According to Hall-Long (2009) in her 
article on nursing and public policy, nurses will get involved to a point but are still not as 
actively involved in the legislature as many other health professionals.  However, as 
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nurses enter into advanced practice, they are beginning to understand that sometimes 
taking care of a patient means serving as patient advocates, which may encourage them to 
leave the bedside comfort zone and venture into the political arena. Nurses can draw 
upon the bedside experience to influence public policy to better serve the needs of the 
patients they wish to help (Maryland & Gonzalez, 2012).  According to Maryland and 
Gonzalez (2012), nurses can influence public policy through advocacy by providing real 
life examples to illustrate the needs of patients and the outcomes of public policy on 
patient morbidity and mortality.  Nurses can advocate for increased access to care, which 
is certainly needed in the case of the patients who are addicted to opiates.  
There is a lack of services available to those with opiate addiction, a lack of 
treatment facilities and a lack of access to emergency measures such as naloxone to 
families and non-physicians, despite the fact that these individuals are most likely to 
come into contact with an individual who has overdosed.  Since healthcare costs, access 
and quality outcomes are a large part of many political agendas, the nurse is in a perfect 
position to influence these agendas due to the inherent trust the public and patients have 
in the nursing profession (Maryland & Gonzalez, 2012).  “When nurses have the ability 
to share experiences and insights with public and elected officials, they can advocate for 
patients and families effectively and become a powerful force in the policy-making 
process” (Maryland & Gonzalez, 2012, p.2). 
The Leadership Role of the APN in Opiate Addiction Treatment 
The APN leadership role in health policy can be effective at an individual level or 
through groups of APNs who share a common interest or goal in patient outcomes.  
According to  Filipovich (2013), “Leadership in any form requires current knowledge of 
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the issues that affect nursing and health care as well as how policy decisions pertaining to 
those issues are made” (Kindle Locations 3746-3748).  The APN is ideally positioned to 
take a leadership role in policy due to the knowledge base required at that level of 
practice. In the case of opiate addiction, effective advocacy on the part of the APN 
requires assuming a leadership role and knowing effective strategies to promote 
legislation that would increase treatment options for those addicted to opiates.  Assuming 
a leadership role would mean organizing efforts to lobby politicians, creating a coalition 
to fight for the increased treatment option availability for addicts and organizing the vast 
scientific research that backs the efforts of increasing naloxone availability to families of 
people addicted to opiates and emergency personnel that come into contact with the 
overdosed individual.  The APN has the expertise needed to spearhead efforts to teach 
family members about the safe administration of naloxone, as well as prevention, 
treatment and aftercare of an overdose.    
 Advanced practice nurses make ideal leaders because they are educated for a 
political journey, according to Hall-Long (2009).   She asserts that the skills she gained 
from her nursing education, such as communication, advocacy, listening, problem-
solving, and reflection, have proven to be essential in times of political compromise.  
These skills have made her an effective leader who eventually became a Delaware 
legislator.  Nurses are excellent communicators, listeners and multitaskers and receive a 
high level of public respect, positioning them effectively in leadership.   
The Lobbyist Role of the APN in Opiate Addiction Treatment 
According to Milstead (1997), the clinical expertise of APNs translates well into 
the political arena.  Milstead (1997) states that bringing a problem to the attention of the 
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government is often the first step in solving it.  APNs can use their expertise to provide 
fact sheets, statistics and personal experiences to bring a problem to the attention of 
legislatures (Milstead, 1997).  APNs have expert knowledge to share and are skilled at 
synthesizing the available research on a topic in order to lead an evidence-based 
discussion of the issue.  APNs know how to tap into available resources within 
communities, and they know what services are available and needed.  APNs can look at 
the multifaceted scope of a problem and approach it from an evidence-based perspective.  
In reference to opiate addiction the APN is able to share the experiences of treating those 
with opiate addiction and provide the statistics on relapse, lack of treatment resources and 
mortality rates due to overdose. In addition to evidence, the APN can provide personal 
experiences with individuals with opiate addiction who want to detoxify from opiates but 
have neither the willpower to do so on their own nor the money for a private drug 
rehabilitation treatment facility.  The APN can share the stories of families who worry 
daily whether they will find their son or daughter dead from a heroin overdose and who 
would have some relief if they had naloxone on hand to administer in an emergency.    
Conceptual Framework 
Kingdon (2012) developed the streams metaphor to describe how issues become 
part of policy-making agendas, emphasizing that this occurs when the problem, policy 
and political streams merge at the same moment, thus creating a window of opportunity 
for change to occur.  The problem stream describes the issue or problem at hand.  It 
involves the process of persuading those in power to view a certain problem as the one 
that should get their attention at a specific time when there are always competing 
problems for the agenda.  It also involves convincing lawmakers that the problem can be 
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reduced or eradicated by the policy presented instead of the other solutions or alternative 
approaches. According to Kingdon, the policy stream encompasses all possible solutions 
to the problem that the lawmakers could pursue within the timeframe and political 
climate present. Within that climate, Kingdon observes that streams converge and may 
create a window of opportunity for a policy to become a law.  Strategies include focusing 
events in order to bring problems to the public forefront, thus making it an issue that is 
ripe for the “window of opportunity” (Kingdon, 2011).  Heroin overdose and opiate 
addiction are reaching epidemic proportions and overdose deaths of celebrities bring the 
issue into the public eye; thus the problem is being brought to the public forefront. Now 
may be the perfect time for APNs to offer solutions to the problems and to lobby for 
increased treatment options and access to treatment for opiate addicts.  
Kingdon’s Streams Model (Figure 1)  
Problem Stream 
 
 
Window 
 
Policy Stream 
 
 
of 
Politics Stream 
 
 
Opportunity 
TIME 
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Application of Kingdon's concepts to promote policy change requires a clear 
understanding of the problem of opiate addiction and how it came about in the United 
States.   
The Problem of Opiate and Heroin Addiction 
    Historical Perspective 
 Opiate addiction originated in this country around the time of the Civil War 
(Courtwright, 2001).  Why then?  Around 1840 New Englanders brought the first 24,000 
pounds of opium into the United States.  Since then, the face of opiate addiction has 
changed many times in the populations affected, prompting a response from the country’s 
social, political, legal and medical communities (Courtwright, 2001).  Opioid addiction 
has been primarily viewed through two different lenses: (1.) it is an incurable disease 
requiring long term maintenance with drug replacement therapy and (2.) it is caused by a 
personality flaw or lack of moral character and is best treated by abstinence or by 
punitive measures in the criminal justice system.  Stigma and empathy toward people 
addicted to opiates have waxed and waned depending on the population most affected. 
For example, in the late nineteenth century an estimated 300,000 persons with opiate 
addiction were mostly either female upper class or disabled war veterans, thus this 
population was treated with empathy (Courtwright, 2001).  The population changed, 
however, with the introduction of heroin as a “cough suppressant” and injectable forms of 
drugs which contributed to increased use among street criminals, changing the attitude of 
empathy to one of disdain and stigma (Courtwright, 2001).  
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Post World War II, the population of those with opiate addictions shifted to the 
inner city ghetto areas and the attitudes toward this population seemed to shift towards 
stigmatization and further away from empathy. During the subsequent period, 1960-1980, 
approximately 500,000 Americans of all social and economic backgrounds used opioids, 
thus creating a major medical problem and a social “hot button” topic (Courtwright, 
2001).  According to SAMHSA data on drug use for 2012 approximately 898,000 people 
in the United States were using heroin, treatment admission rates for addiction to opioid 
analgesics more than doubled between 1992 and 2001, and emergency room visits related 
to opiate abuse increased 117 percent between 1994 and 2001 (SAMHSA, 2012).  
Some medical problems are more prevalent in people addicted to opioids than in 
the general population. Many of the problems include infections that can be life 
threatening, such as cellulitis, wound botulism, necrotizing fasciitis, and endocarditis. 
Diseases that are transmissible pose serious public health threats, such as HIV/AIDS, 
hepatitis, syphilis, and tuberculosis (TB).  Many patients in medication-assisted treatment 
(MAT) for opioid addiction have chronic diseases such as diabetes, asthma, or 
hypertension, as well as conditions such as severe dental problems or seizure disorders, 
which may have been neglected or poorly managed for years. Some patients have chronic 
obstructive pulmonary disease (COPD), hypertension, coronary artery disease, or other 
illnesses related to long-term heavy tobacco use. Management of chronic pain for patients 
in MATs is particularly challenging because of the role of opioids in pain treatment. In 
addition, opioid intoxication may result in head trauma or other bodily injury. Criminal 
activity may produce severe physical injuries such as gunshot wounds.  
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 While methadone, buprenorphine and naltrexone are all used to assist with 
treating the chronic addiction to opiates, there still remain issues with lack of access to 
these treatment options.  Moreover, current public opinion still vacillates between 
blaming those with addiction and following a punitive approach versus recognizing 
addiction as a disease to be treated.  As Olsen and Sharfstein (2014) point out, “First, the 
understanding of opioid use disorder as a medical illness is still overshadowed by its 
misconception as a moral weakness or a willful choice” (p.1393).  Even in the substance 
use treatment community, many still believe that recovery depends solely on the 
willpower to abstain from all opioids, including methadone and buprenorphine (Olsen & 
Sharfstein, 2014).  Furthermore, many treatment facilities require those who receive drug 
replacement therapy to taper off or discontinue and detox to be considered a success at 
treatment (Olsen & Sharfstein, 2014). As such, “Reimbursement for treatment may cover 
only the most basic services, including medication delivery and a weekly professional 
encounter” (Olsen & Sharfstein, 2014, p. 1394).  Since opiate detoxification is not 
considered life threatening, most insurance companies and hospitals refuse patients based 
on the sole admitting diagnosis of opiate detoxification.  Moreover, the patient usually 
has to have suicidal ideation or a co-morbid condition for admission. Olsen and 
Sharfstein (2014) have also noted that the language used to describe opiate addiction is 
stigmatizing. For example, the active user is called “dirty” while those who are not using 
are described as “clean.” “Junkie” is still a popular term to describe both opiate and 
heroin addicts (Olsen & Sharfstein, 2014).   
The history of how opiates came into the country and how they created the 
opportunity for addiction across all socioeconomic spectrums is fascinating. Next, 
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Kingdon's model recommends an examination of possible solutions to the problem of 
opiate addiction within the present timeframe and current political climate to determine 
the likelihood of the three streams converging to create the window of opportunity 
(Kingdon, 2007). 
 The Policy of Opiate and Heroin Addiction      
 Application of the Kingdon policy stream concept calls for exploration of all 
potential solutions to the problem that are available to decision makers (Goshin & Byrne, 
2009).  Therefore, it is important to begin the exploration by recognizing that opiate 
addiction is typically viewed as either a medical illness or disease and treated with 
interventions or it is viewed as a moral weakness with incarceration.  If treated, four 
options are generally available: detoxification, methadone maintenance, buprenorphine 
replacement therapy and naltrexone (aversion therapy).   However, due to lack of 
insurance coverage and lack of availability of treatment facilities available to those 
without funds, these treatment options may not necessarily be available to those who are 
addicted to the drug.  Legislative efforts can address the problem, and the APN is in a 
position to help enact effective legislation to help the treatment of those with opiate 
addiction.       
Legislative approaches 
Senate Bill 5 is an example of a recent legislative approach in the state of 
Kentucky to increase the treatment options available to those with opiate addictions.   
Although legislation is not intended to completely resolve the problem, it is an important 
approach for easing the burden of opiate overdose in Kentucky.   In addition, it addresses 
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an important public issue related to the hundreds of fatal heroin overdoses in Kentucky 
during the past three years as well as the crimes committed by those suffering from 
heroin addiction, for the money required for their drugs.  The proposal for the bill 
included use of Medicaid programs in the state to cover several inpatient and outpatient 
options for people with opiate addiction and it encompassed heroin and prescription drug 
abuse problems as well. The bill specified expansion of treatment programs for the opiate 
addicted population because Kentucky currently has only about 2,400 treatment beds for 
those addicted to substances. The deficit in available treatment beds results in wait lists of 
six months or longer for treatment – a time frame that is untenable for those who need 
help.  Senate Bill 5 also sought to increase the availability of naloxone and make it 
available to families of those with addictions and emergency workers.    
Treatment options 
 Methadone is a limited treatment option because it is only available through 
specialized treatment clinics (National Institute of Health, 2010).   Also, use of 
methadone replacement therapy is often met negative opinions and stigma.  Patients 
undergoing this treatment may be made to feel that they are just replacing one drug for 
another, that they are somehow morally, physically, or spiritually weak for not being able 
to be completely free of all substances.  Another option is buprenorphine which is used 
for detoxification and relapse and does not require inpatient admission.  Two types of this 
medication exist.  Suboxone (buprenorphine),  gives the euphoria and feeling of well-
being similar to the abused drug of choice but at a safe prescription level and dosage, 
simultaneously blocking any opiate receptors in case the patient were to use opiates while 
on the drug.   Subutex, is purely an opiate agonist which does not give the euphoria or 
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feeling of well-being.  Therefore, subutex is often favored as the drug to give, yet those 
with addictions are often not as adherent with this therapy.  Naltrexone is an opioid 
receptor blocker that not only blocks heroin overdose but in the depot injection form of 
Vivitrol® can be effective for long periods, diminish opioid use, reduce craving and 
promote patient adherence to treatment (National Institute of Health, 2010).  However, 
Vivitrol® is expensive and therefore cost prohibitive to a large percentage of those with 
addictions.   
The Politics of Opiate and Heroin Addiction 
The politics stream involves the political climate and the public opinion about the 
issue and policy solution being presented.  With the current administration, Kingdon’s 
window of opportunity on a national level is wide open.  The window was open 
nationally for a bill like Senate Bill 5 to be successfully passed, but would it be in the 
state of Kentucky?  According to Schambra (2009), “Both his ambition and his unique 
style of issue management show that Obama is emphatically a policy approach president” 
(p.127).  Schambra (2009) states that Obama’s policy approach looks at long term 
problems of healthcare, taking into account the whole and avoiding attempts to solve the 
problem in small pieces.  Obama has demonstrated an approach to the national drug 
problem by looking at objective evidence, scientific facts and expert counsel by the 
formulation a Nation Drug Control Strategy in 2010.   
On a national scale, the Obama administration has attempted to change drug 
abuse treatment and perspective through development of new policy based on scientific 
research instead of ideology in his administration. The 2013 National Drug Control 
Strategy emphasized that government policy has shifted from that of incarceration 
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focused solutions to a drug prevention approach incorporating strategies informed by 
science, research and evidence.  The strategies emphasize prevention instead of 
incarceration.  The strategy also empowers health care professions to intervene early 
before a condition becomes chronic thus creating access to treatment a reality.  In 
addition, the strategy gives a voice to those in addiction recovery, and reinforces the idea 
that the United States cannot arrest and incarcerate its way out of a drug crisis. Rather, it 
views drug issues as being a global problem in “the spirit of shared responsibility” 
(Office of National Drug Control Policy, 2012).        
Political viewpoints 
   Two political viewpoints on drug addiction that are prevalent in America today.  
One viewpoint maintains that addiction is a disease that needs to be treated with 
prevention, education, medical intervention and rehabilitation efforts.  In contrast, the 
other view is based on personal responsibility and the idea that addiction is a path chosen 
by persons who lack fortitude or character.  Some politicians argue that if drug use is a 
voluntary activity in which the risk is known, then responsibility falls on the person 
engaged in the activity (Winkler, 2002).  These same individuals would argue that the 
government should not put money and effort into treatment for the opiate and heroin 
addicted population.  
 Policy Options and Outcomes 
The political climate in Kentucky regarding opiate addiction is favoring treatment 
for those with addictions through drug replacement therapy combined with rehabilitation 
efforts.  In an editorial for the Lexington Herald-Leader, Eblen (2008), pointed out that 
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more than 375,000 Kentuckians need drug or alcohol treatment. He argues that for an 
investment of $1 spent on treatment, $7 is saved in health care and criminal justice costs. 
One could try other options such as legislation that would mandate drug testing before a 
patient receives Medicaid, disability or other governmental assistance; yet it would likely 
fail because it would be extremely costly to enforce.  Another option could be promotion 
of abstinence in the school systems as a preventative measure. However, previous Just 
Say No campaigns have not proven to be effective in curbing the appeal of drugs 
(Rosenbaum, 1998).  One could also continue the current approach of prosecuting the 
drug dealers, especially in areas where the drug abuse problem is rampant. However, that 
approach does not appear to be working at this time.  According to Kleiman (2001), 
“Neither current drug policies nor current correctional policies offer any real hope of 
substantially reducing drug consumption by user/offenders” p. 171.   Other options 
include incentives to those addicted who remain drug free, which is what was done with 
some success in a study of pregnant opiate users by Svikis, Lee, Haug, and Stitzer (1997), 
but that would not be cost effective and again, it would be difficult to enforce.  
 Case Study:  Senate Bill 5 
The legislation proposed for enactment of Senate Bill 5 would have furthered the 
goals of the current National Drug Control Strategy.  For example, Senate Bill 5 would 
have amended current legislation and redirected a portion of the recaptured savings from 
criminal justice reforms be directed to funding of treatment programs for those suffering 
from opiate addiction.  It would have created a new section of Kentucky Revised Statute 
(KRS) by specifying that controlled substance treatment services be offered under 
Medicaid and would thus increase treatment availability to opiate addicted populations.  
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It would have also amended the current KRS 217.186 by allowing for the availability of 
naloxone for use as a rescue drug for narcotic overdose situations.  This would save lives 
in the case of overdose emergency situations and create a safe harbor by enacting a new 
section of KRS Chapter 218A to provide immunity for persons seeking emergency help 
in drug overdose situations.   
The goals proposed by Senate Bill 5 would have moved away from a punitive 
approach of opiate drug addiction toward a recovery based treatment modality based on 
the evidence of scientific research as the most effective approach in the treatment of 
addiction.  Furthermore, goals of the bill were consistent with the National Drug Control 
Strategy set in 2010, which based its strategy on scientific research and inquiry.       
Senate Bill 5 did not garner sufficient votes to be passed into law.  An apparent 
filibuster in the Kentucky House in the final hour of the General Assembly session 
prevented it from passing. The three streams converged and the “window of opportunity” 
seemed to be conducive to the possibility of passing the bill. The concepts contained 
within the bill are still valid, worth reconsidering and fighting for by APNs interested in 
promoting treatment options and decreased mortality rates for opiate-addicted 
individuals.  
Conclusion 
     The problem of opiate drug addiction and death from overdose will require a 
comprehensive solution that will include input and a multidisciplinary approach from 
healthcare providers, policy makers, public health officials, law enforcement and 
legislators.  However, much evidence suggests that an effective strategy to reduce the 
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number of deaths from overdose is to remove the legal barrier to obtaining naloxone 
(Wermeling, 2010).  The APN is in the position to advocate for families of those with 
addiction themselves, to provide some relief from worry.  The “window of opportunity” 
appears to be ripe for the APN to lobby on behalf of this vulnerable population and save 
lives.   
 
Addendum from Senator Stine 
Sponsor of Senate Bill 5 
     When asked if she was going to pursue this issue the next legislative session she 
responded with this email:  
“ Thank you for your email about last session’s SB5. I am not running for re-
election so I will not be a member of the Senate when it convenes in January because 
my present term will have ended at the end of 2014. In these last days of my term I 
have been traveling around the state visiting treatment centers, community leaders 
and law enforcement officials trying to raise consciousness about the real threat that 
heroin poses to our state. It is a tragedy that the House chose to ignore this 
important legislation until the last day of the session and then load it down with 
“ripper” amendments so that they ran  out of time and failed to pass SB5 in the 
session. Please encourage your legislators in your part of the state to take action. 
Unfortunately people are dying due to this inaction. If this many lives were lost due 
to some unknown virus or natural disaster there would be a huge response and 
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outcry. Why are blind eyes being turned toward the heroin epidemic and its terrible 
cost in Kentucky lives?  
Thanks again  for contacting me.” 
Senator Katie Stine 
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ABSTRACT 
 
 This paper explores the treatment needs of opiate addicted pregnant 
women by assessing their preferred method of treatment when hospitalized on an 
inpatient behavioral unit at a large medical center in a southeastern state of the United 
States.  The period of assessment was a one year time frame and the study is a 
retrospective case review of charts from 161 patients who were hospitalized at that time.  
The research questions to be answered included what is the preferred method of treatment 
for opiate addicted pregnant women when they are initially hospitalized and how is 
frequency of prn usage during treatment associated with their disposition at discharge?  
Findings from this study may initiate discussions on what retains a patient in treatment, 
what is important to do for the patient while in treatment, and what could be the long-
term treatment needs to maintain drug abstinence and improve quality of life. 
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Problem Statement  
 Opiate addiction among pregnant women is a national epidemic that has risen 
sharply since 2000 (Patrick, 2012).   The number of newborns with neonatal abstinence 
syndrome (NAS) defined as the withdrawal syndrome of the newborn of an opiate 
addicted mother,  tripled between 2000 and 2009 and the number of mothers using 
opiates at delivery increased five-fold (Patrick, 2012).  Additionally, maternal opiate use 
at the time of delivery in the United States increased from 1.19 to 5.63 per 1,000 births 
during the years 2000 to 2009 (Patrick, 2012).  The costs of treating NAS in 2009 was 
720 million dollars; 77.6% of this cost is paid by state Medicaid programs (Patrick, 
2012).   
 According to Stone (2015), pregnant women who misuse substances are 
positioned at the center of public health and criminal justice intervention.  “The impact of 
their substance use on their personal health and the health of their fetuses is a public 
health concern, as professionals in this field are dedicated to improving maternal and 
infant health” (Stone, 2015, p. 1).  This places the woman at a disadvantage since as she 
is subject to criminal prosecution, increased surveillance, loss of custody of her child, and 
prosecution if she seeks assistance for her addiction issues and is an active user.   
The overall goal of this Doctor of Nursing Practice (DNP) program practice 
inquiry project was to determine the most effective inpatient treatment methods for opiate 
addicted pregnant women.  The immediate objective was to conduct a retrospective chart 
review of previously hospitalized opiate addicted pregnant women to ascertain the 
treatment preferences of the women and to see if there was a correlation in prn usage and 
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disposition at discharge. This type of analysis has the potential to help clinicians create a 
blueprint for effective treatment of this special population and thereby increase treatment 
retention and success.  In addition, this group of women is a very specific population with 
specific needs.  Most of them, when identified as pregnant and opiate addicted, are 
referred for short term hospitalization for opiate detoxification or treated with methadone 
or suboxone as a safer substitute (Veilleux, Colvin, Anderson, York, & Heinz, 2010).  They 
often have difficulties withdrawing from opiates whether they are placed on 
detoxification or whether a drug replacement with methadone or suboxone is utilized 
(Veilleux et al., 2010).  This study was designed to uncover which treatment modality is 
utilized most often by the women in general and what, if any, differences are found in 
need for adjunct medication for each treatment approach.    
Research Questions 
What is the preferred method of treatment for opiate addicted pregnant women 
when they are initially hospitalized and how is frequency of prn usage during treatment 
associated with their disposition at discharge? 
Background and Significance 
     Illicit drugs were consumed by 5.1% of pregnant women in the United States in 
the year 2009, compared to 9.3% of women in the general population (Young, 2009).  
The prevalence rates of substance abuse during pregnancy ranged from 1.3 to 18% during 
the 1990s, with the rates increasing over the past two decades (Bertsch, Mullins, & 
Chaffin, 2006).   It is important to note that the infants of women with opiate addiction 
were born with NAS, which resulted in significant respiratory distress, low birth weight, 
feeding difficulties and seizures. Also, the newborns with NAS were more likely to be 
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covered by Medicaid.  According to Patrick (2012), mean hospital charges for these 
infants rose from $39,400 to $53,400 between 2000 and 2009, compared with a rise from 
$6,600 to $9,500 for all other hospital births over the same period.  Solutions to decrease 
the number of opiate users and newborns exposed to opiates should be of utmost concern 
and priority due to the risks it poses to the newborn child and the high healthcare costs 
associated with treating the newborn with NAS.   
Theoretical Framework 
 
     The study’s theoretical framework is the Disease Model of Addiction.  The 
Disease Model of Addiction proposes that addiction of any kind has biological, 
neurological, genetic, and environmental sources of origin.  The disease model involves 
set factors that make a person susceptible to addiction be it either genetic predisposition 
or psychological damage that occurred during childhood or both factors (Peele, 1988).  
When this susceptible person is exposed to drugs and or environmental stress then drug 
addiction is likely to result which then leads to a host of other problems.  This model fits 
when applied to the women in this study as the majority of the women reported a family 
member with addiction issues and a large majority of the women also reported a history 
of sexual abuse as a child or adolescent and current physical abuse in relationships.   
Design and Methods 
 DESIGN: 
   The proposed study was based on a descriptive retrospective medical record 
review of opiate addicted pregnant women hospitalized on a behavioral unit at a large 
medical center in a southeastern state of the United States and that all study procedures 
were approved by the medical review board of the sponsoring institution. 
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SAMPLE: 
     The convenience sample consisted of all pregnant opiate addicted women 
hospitalized at Samaritan Hospital Behavioral Health from January 1, 2012 to December 
31, 2012.   
MEASURES/INSTRUMENTS: 
Demographic Variables: Demographic variables included years of age, ethnicity, 
educational level, marital status, and presence of existing psychiatric disorder and type of 
opiate used (heroin, oxycodone etc.), age of first use, years of use, number of previous 
detoxification attempts, whether they are a tobacco smoker, gestational age of fetus and 
how many living children they had currently not counting present pregnancy.    
Outcome variables: The primary outcome variable was preferred method of treatment 
(detoxification, methadone maintenance, subutex)  as stated by the patient upon 
admittance to the inpatient facility.  The secondary outcome measure was amount of 
PRNs used (in counts) from day 1 to day 5 of inpatient hospitalization. In addition, the 
average prn usage (across the 5 days of admission) were determined. Finally, information 
on discharge disposition [detoxification vs. methadone maintenance vs. suboxone 
(buprenorphine) vs left Against Medical Advice (AMA)] was obtained from the charts. 
PROCEDURE: 
  The sources of research material were obtained from the medical charts of 
previously admitted patients on a behavioral health unit who had a diagnosis of opiate 
addiction and pregnancy.  Since this study involves a retrospective chart review of 
existing data, no subjects were recruited.  No identifiers were obtained from subject 
charts and each chart reviewed was given a unique code. An official letter of support 
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from the major medical center granting access to the charts for this research purpose was 
granted, giving permission for this research record review.  Medical record personnel 
were utilized to obtain the charts once IRB permission was granted.  The IRB approval 
processes were followed and the procedure for a Medical Expedited Exempt IRB Review 
was followed. Once the research study was approved, data was securely stored on 
removable device kept with the researcher.  The sample included medical records of all 
pregnant women with opiate addiction hospitalized at Samaritan Behavioral Health 
during a specific time period (Jan 2012 to Dec. 31, 2012).    
DATA ANALYSIS: 
 The primary outcome measure was an analysis of the preferred method of 
treatment as stated by the patient upon admittance to the inpatient facility.  Differences in 
treatment completion were calculated using chi-square analyses for categorical and 
ordered categorical values (with Fisher’s exact test for cells with lower than expected cell 
count), and using t-tests or Mann-Whitney U tests for continuous variables (which did not 
meet the assumption of equality of variance based on Levine’s equality of variance test).   
The secondary outcome measure was amount of PRNs used from day 1 to day 5 
of inpatient hospitalization and how it related to disposition at discharge.  Analysis of 
Variance (ANOVA) tests were used to assess mean differences in total and average 
(across the 5 days) prn usage by disposition at discharge (i.e., detox vs. methadone 
maintenance vs. suboxone (buprenorphine) vs left AMA).  
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Results 
Sample Characteristics 
 The sample included 161 women. The sample was primarily white (96.3%), 26.4 
years of age, high school or GED (65.8%).  One-half of the sample were single and not in 
a relationship and were an average at 19.7 weeks of gestation.  The majority were 
tobacco users (91.3%) and using opiates in general (42.2%) or a combination of opiates 
and other illicit drugs (34.8%).  On average women started using opiates at age 19.3 and 
had been using for nearly 7 years.  More than one-third of the women had a co-morbid 
psychiatric illness.  Of those attending the methadone inpatient program, 80.7% 
completed (stayed 5 days).  There were no significant differences in patient 
characteristics between those who completed and did not complete the program (See 
Table 1). 
Preferred Method of Treatment During Hospitalization 
 When women were asked their preferred method of treatment, the majority 
preferred detoxification (see figure 1).  The preference for method of treatment did not 
vary by demographic or other patient characteristics.   
Association between PRN use and Discharge Disposition 
 There were significant differences in the frequency of PRN use by patients’ 
disposition at discharge. Patients who left before treatment was complete/AMA, had 
significantly lower scores on total PRN use and average PRN use as compared to those 
who preferred to be detoxed from opiates or who had plans to be maintained on subutex 
or methadone upon discharge.  Specifically, patients who left early/AMA or before the 5 
days of treatment used less PRNs (Mean amount of total prn use =  5.6) whereas 
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participants who stayed the entire 5 days of treatment and did not leave AMA used more 
PRNs (Mean amount of total prn use = 13.2).  Patients who left before treatment was 
complete/AMA, had significantly lower scores on total PRN use and average PRN use as 
compared to those who preferred to be detoxed from opiates or who had plans to be 
maintained on suboxone, subutex or methadone upon discharge (see Table 3).  As 
indicated in Table 3, average PRN use among non-completers/AMA was lower compared 
to completers or those who were detoxed from opiates or chose maintenance medications  
Discussion 
The standard of care for an opiate addicted pregnant woman would necessitate a 
universal substance use screening during pregnancy and referral to treatment such as 
maintenance therapy if warranted (Mattick et al., 2009).  Evidence based practice and a 
review of the literature suggests that when identified as pregnant and opiate addicted, 
women are referred for short term hospitalization for opiate detoxification and then 
treated with methadone or suboxone as a safer substitute on a maintenance basis (Martin 
et al., 2014: Kahila et al., 2007).  A comprehensive, standard of care program regimen 
improves maternal and neonatal outcomes as well as reduces associated adverse health 
consequences (Jones, O’Grady, Malfi & Tuten, 2008; Kaltenbach & Finnegan, 1998).  
Methadone, Suboxone and Subutex treatments, also known as drug replacement therapy, 
is the preferred alternative to detoxification according to most research, as research has 
shown that it is safer and more effective for the addicted mother and fetus. 
The treatment needs as expressed by the study sample did not match what the standard of 
care suggests.  Greater than 90% desire to detoxify from drugs completely as verbalized 
by the patient (see Figure 1).  No other study, known to this author, have asked patients 
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their preference for treatment.  Addicted women who completely detox often relapse if 
they do not go to extended treatment and receive drug replacement therapy (Kahila et al., 
2007).  However treatment and drug replacement therapy is often difficult to obtain and 
afford, which may have affected the participants’ stated choice of “detox.” In addition 
they may have endorsed detox because participants felt that it was the “right” thing for 
their unborn child.  Nonetheless, this finding is consistent with the findings according to 
Martin et al.,  (2014), who state that only about a third of the women hospitalized when 
pregnant for opiate addiction are placed on medication assisted therapy despite the 
standard of care for opioid abuse in pregnancy.   
 Alternatively, the poor endorsement of drug replacement therapy at discharge by 
the study sample may reflect the lack of available and accessible treatment facilities to for 
this population and the financial limitations that come with such treatment.  This is 
consistent in other studies that highlight the multiple barriers pregnant women with 
addition problems face with a lack of suitable treatment options and challenges in finding 
and accessing treatment (Stone, 2015).  These potential barriers necessitate the further 
expansion of treatment programs and social services to meet the needs of substance-using 
women (Stone, 2015). This need is highlighted by a qualitative study with 30 cocaine 
using women that found that optimizing the benefit of comprehensive services for 
addicted women requires their provision within a multilevel model of substance abuse 
treatment, including long- and short-term residential and intensive outpatient settings 
(Kaltenbach and Finnegan, 1998).    
 In addition, in the current study, PRN use was significantly associated with 
discharge disposition.  The more the study sample received PRNs, the more likely they 
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were to stay the entire detoxification period and not leave against medical advice.  Those 
who left against medical advice received the fewest PRNs; this finding was significant 
when examining both total PRN usage and when examining PRN usage based on the total 
stay. This could suggest that comfort level of the patient may be a factor in the patient 
completing treatment.  Those who ask for and receive PRNs may be trying to decrease 
their discomfort while those who are not may have lower tolerance for withdrawal or be 
less motivated to engage in treatment.   Often those patients who left AMA were patients 
who returned again once or twice for detox during the same pregnancy.  This is consistent 
with other studies which reported that few opioid addicted women can handle abstinence 
from opioids (Unger et al., 2010; Martin et al., 2009).   
Limitations 
 The limitations in this study include the small sample size (161) and the fact that 
it encompasses a geographic region that may not capture true demographics typical of the 
population at large.  In this study, for example, 96.3% of the participants were White, 
which may lead a researcher to believe it is not a problem for other ethnicities.    
An additional limitation is that since this study is a retrospective analysis of existing data, 
there could have been different study variables which could have affected the outcomes 
of the study that were unavailable. For example, the data on participants’ withdrawal 
scores were unreliable because there were too many missing records from the charts.  In 
other words, often times opiate withdrawal checks were not done the requisite or ordered 
times that they were supposed to be done.  In addition, participant’s motivation for detox 
was not measured. As a result, it is not possible to tell if those who left AMA were less 
motivated to complete treatment as compared to those who completed treatment. Future 
 
 
57 
studies may assess patient motivation as a possible predictor of discharge disposition and 
treatment completion.  
 A strength of this study is that it is the first of its kind.  Opiate addiction among 
pregnant women is a subject which has been reviewed extensively for neonatal 
abstinence effects and the effects of drug replacement therapies but it has not been 
reviewed in terms of the patient experience, preference for treatment and success of 
treatment long term for the woman and her children.   
Implications for Practice 
 This study can be used as a beginning blueprint for investigating what pregnant 
women with opiate addiction need for treatment from an inpatient perspective.  It can 
begin the discussion on what retains a woman in treatment, what is important to do for 
the woman while she is in treatment, and what could be her treatment needs long term in 
order for her to remain drug free and improve her quality of life?  It can help healthcare 
workers examine the stigma they place on the opiate pregnant addicted woman and shape 
attitudes and practice.   
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Table 1. Sample characteristics by program completion 
 Total 
(N =161) 
Completed 
(n = 130) 
Not Completed 
(n = 31)  
 N % n % n % 
Ethnicity       
White 155 96.3 124 95.4 31 100.0 
African American  4 2.5 4 3.1 0 0.0 
Hispanic  1 0.6 1 0.8 0   0.0 
Other 1 0.6 1 0.8 0 0.0 
       
Education Level (missing=12)       
Less than High School 51 34.2 44 34.9 7 30.4 
High School/GED or greater 94 63.1 79 62.7 15 65.2 
College Graduate 4 2.7 3 2.4 1 4.3 
       
       
Marital Status 
Single, not in relationship 
 
82 
 
50.9 
 
73 
 
56.2 
 
9 
 
29.0 
Divorced/Separated 18 11.2 14 10.8 4 12.9 
Non-Married, Living with Partner 37 23.0 25 19.2 12 38.7 
Married 19 11.8 13 10.0 6 19.4 
Non-Married, estranged from Partner 2 1.2 2 1.5 0 0.0 
In relationship, not living with Partner 3 1.9 3 2.3 0 0.0 
       
 
Type of Illicit Drug Use  
      
Heroin 10 6.2 7 5.4 3 9.7 
Opiates in General 68 42.2 55 42.3 13 41.9 
Oxycodone/OxyContin 23 14.3 18 13.8 5 16.1 
Suboxone 2 1.2 0 0.0 2 6.5 
Methadone 2 1.2 2 1.5 0 0.0 
Combination of Many 56 34.8 48 36.9 8 25.8 
       
Tobacco Use       
Yes 147 91.3 118 90.8 29 93.5 
No 14 8.7 12 9.2 2 6.5 
       
Co-Morbid Psychiatric Illness       
Yes 60 37.3 52 40.0 8 25.8 
No 101 62.7 78 60.0 23 74.2 
       
Number of Detox Attempts       
None 70 43.5 54 41.5 16 51.6 
1 to 3 69 42.9 57 43.8 12 38.7 
Greater than 3 22 13.7 19 14.6 3 9.7 
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*** Differences are calculated using chi-square analyses for categorical and ordered categorical values (with Fisher’s exact test for 
cells with lower than expected cell count), and using t-tests or Mann-Whitney U tests for continuous variables (which did not meet the 
assumption of equality of variance based on Levine’s equality of variance test).   
 
 
 
      
Table 2       
 Mean SD Mean SD Mean SD 
Age (years) 26.4 4.4 26.3 4.5 27.0 3.7 
       
Gestational Age of Fetus (Weeks) 19.7 8.0 20.1 7.9 17.9 8.4 
       
How Many Living Children  1.5 1.9 1.5 1.9 1.5 1.8 
       
Age of First Use of Opiates in Years(missing = 4) 19.3 4.4 19.2 4.3 19.9 5.0 
       
Duration of Use in Years (missing = 4) 6.9 4.9 6.8 4.8 7.3 5.6 
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Figure 2 Preferred Method of Treatment 
  
91.3%
8.7%
What is your preferred method of 
treatment?
Detox
Methadone Maintenance
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Table 3. Differences in Frequency of PRN use by Disposition at Discharge and 
Completion of Treatment 
 Total PRN 
 Mean SD F Statistic (DF) P-Value 
Disposition at Discharge   7.0 <.0001 
Methadone Maintenance (n=20) 12.3 7.9   
Detox from Opiates (n=101) 14.2 8.5   
Maintenance on Subutex (n=15) 13.2 10.5   
Left on no RX/AMA (n=25) 5.6 6.5   
     
 Average PRN*  
 Mean SD F Statistic (DF) P-Value 
Disposition at Discharge   3.7 .013 
Methadone Maintenance (n=20) 2.5 1.6   
Detox from Opiates (n=101) 2.9 1.7   
Maintenance on Subutex (n=15) 2.8 2.2   
Left on no RX/AMA (n=25) 1.7 1.4   
Average PRN use is defined by the total PRN use/length of stay 
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Practice Inquiry Project Conclusions 
 
Opiate addiction is a complex multidimensional disease that affects every aspect 
of the afflicted person’s life.  This problem becomes more urgent during pregnancy, 
because another life is involved.  The evidence based literature has demonstrated the 
degree to which opiate addiction and pregnancy has escalated in scope in this country.  
The literature has also described the attempts at treatments for women who are pregnant 
and opiate addicted with an emphasis on the utilization of drug replacement therapy as 
the safest alternative for the woman and the child.  However, the problems that opiate 
addictions encompass go beyond the pregnancy and expand into psychosocial, 
physiological, psychological, financial, legal and ethical realms.  Thus this problem needs 
the focus of an APN to tackle some of its issues from the policy arena in order to create 
long term lasting effects for the health of this vulnerable population.  The access to 
treatment is limited, and funding for standard drug replacement therapies is lacking.  The 
women then attempt to detox off of all drugs and more often than not fail in that attempt.  
The result even with a woman who receives adequate drug replacement therapy is an 
infant born with neonatal abstinence syndrome, a costly expense to the system.  Women 
who do seek treatment are often stigmatized by society and even by the healthcare 
workers they seek treatment from.  In addition, they often face legal consequences of 
their drug use which could include losing custody of their children when they admit to 
needing help with their drug addiction.   
Why are so many young women abusing drugs?  What are their stressors in life?  
Why do they use drugs when others don’t?  Is prevention a possibility here?  In the 
meantime how do we effectively treat these women in a manner that is consistent with 
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what they want and need?  This research has basically raised several more important 
questions, and this researcher would like to go to the source for the answer, the women 
themselves.   
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